MedDataX Logo

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

NCT ID: NCT00628303

Last Updated: 2012-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the efficacy of motavizumab compared to placebo when administered monthly to preterm infants during their first RSV season for the reduction of the incidence of serious early childhood wheezing from their 2nd through 3rd birthdays.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is assess the efficacy of motavizumab compared to placebo when administered monthly by intramuscular (IM) injection during the first RSV season for the reduction of the incidence of serious early childhood wheezing in preterm infants between their 2nd and 3rd birthdays.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wheezing

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Good health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Motavizumab

Group Type EXPERIMENTAL

Motavizumab

Intervention Type BIOLOGICAL

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

2

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motavizumab

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

Intervention Type BIOLOGICAL

Placebo

15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MEDI-524

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female infants born at 32 \& 1/7 - 35 \& 0/7 weeks GA, determined according to available medical records
* Chronological age of \<6 months of age at randomization
* In good health, in the opinion of the investigator
* Not more than one of the following AAP-defined risk factors:

1. Childcare attendance
2. School-aged siblings
3. Exposure to environmental air pollutants (not including passive exposure to tobacco smoke)
* Ability and willingness of the subject's parent/legal guardian to complete all protocol-mandated follow-up telephone contacts, visits and procedures
* Written informed consent obtained from the subject's parent(s) or legal guardian

Exclusion Criteria

* Diagnosis of CLD of prematurity (also referred to as BPD) or other chronic pulmonary diseases
* Diagnosis of hemodynamically significant CHD, defined as requiring medication or supplemental oxygen for their CHD
* Congenital abnormalities of the airways
* Severe neuromuscular disease, as determined by the investigator
* Previous or concurrent treatment with palivizumab or intravenous immunoglobulin (IVIG)
* Eligible for prophylaxis based on local medical standards and guidelines at participating sites
* Known immunodeficiency
* Previous or current diagnosis of an upper or lower respiratory infection by a medical professional
* Previous or current diagnosis of wheezing, asthma, or other wheezing-related diagnoses
* Hospitalization at the time of enrollment (in case admitted to nursery as part of routine care, infant should only be randomized immediately prior to being discharged)
* Any illness or condition that would preclude long-term survival
* Participation in a trial or an investigational agent for RSV prophylaxis or therapy
* Inability to be followed through their 3rd birthday
Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedImmune LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MedImmune Inc.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MI-CP169

Identifier Type: -

Identifier Source: org_study_id